title: Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
abstract: BACKGROUND
  Over 20% of ovarian cancer patients have preoperative thrombocytosis or hyperfibrinogenemia. We aimed to demonstrate the clinical and prognostic significance of thrombocytosis and hyperfibrinogenemia in high-grade serous ovarian cancer (HGSC).
  
  
  METHODS
  We retrospectively investigated HGSC patients who underwent primary staging or debulking surgery between April 2005 and June 2013 in our institution. None of these patients had received neoadjuvant chemotherapy. Data, including age, performance status, FIGO stage, serum CA125, platelet count, fibrinogen level, and surgical residual disease, were collected. Thrombocytosis was defined as a platelet count greater than 450 × 10(9)/L, and hyperfibrinogenemia was defined as a fibrinogen level higher than 4.00 g/L. Progression-free survival (PFS) and overall survival (OS) were analyzed with the Kaplan-Meier method and log-rank tests for univariate analyses. For the multivariate analyses, Cox regression analysis was used to evaluate the effects of the prognostic factors, which are expressed as hazard ratios (HRs).
  
  
  RESULTS
  A total of 875 consecutive HGSC patients were identified. The median follow-up time was 29 (1-115) months. The median (interquartile range, IQR) preoperative platelet count was 301 (235-383) × 10(9)/L, and 121 (13.8%) women had thrombocytosis. The median (IQR) preoperative fibrinogen level was 3.85 (3.19-4.45) g/L, and 332 (45.9%) of the patients had hyperfibrinogenemia. Both preoperative thrombocytosis and hyperfibrinogenemia were associated with an advanced FIGO stage (p = 0.008 and <0.001, respectively), an increased CA125 level (p = 0.004 and 0.001, respectively), more extensive ascites (p < 0.001 and <0.001, respectively), more extensive residual disease (p < 0.001 and <0.001, respectively) and chemosensitivity (p = 0.043 and <0.001, respectively). In the univariate analyses, hyperfibrinogenemia was associated with reduced PFS (p < 0.001) and OS (p < 0.001). However, thrombocytosis was not found to be a potential predictor of PFS (P = 0.098) or OS (p = 0.894). In the multivariate analyses, hyperfibrinogenemia was an independent predictor of OS (p = 0.014) but not PFS (p = 0.062).
  
  
  CONCLUSIONS
  Preoperative thrombocytosis and hyperfibrinogenemia reflected tumor burden to some extent and thus influenced treatment outcomes, and the fibrinogen level was found to be useful as a prognostic predictor in the HGSC patients.
authors.affiliation: Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, 270 Dong-an Road, Shanghai, 200032, China. lizfeng1231@163.com.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. lizfeng1231@163.com.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Feng
authors.affiliation: Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, 270 Dong-an Road, Shanghai, 200032, China. wenhao_fdc@163.com.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. wenhao_fdc@163.com.
authors.forename: Hao
authors.initials: H
authors.lastname: Wen
authors.affiliation: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. br_fdcc@163.com.|Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. br_fdcc@163.com.
authors.forename: Rui
authors.initials: R
authors.lastname: Bi
authors.affiliation: Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, 270 Dong-an Road, Shanghai, 200032, China. yachenduan900925@163.com.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. yachenduan900925@163.com.
authors.forename: Yachen
authors.initials: Y
authors.lastname: Duan
authors.affiliation: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. yangwt2000@163.com.|Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. yangwt2000@163.com.
authors.forename: Wentao
authors.initials: W
authors.lastname: Yang
authors.affiliation: Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, 270 Dong-an Road, Shanghai, 200032, China. docwuxh@hotmail.com.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. docwuxh@hotmail.com.
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D018394:CA-125 Antigen / Q000097:blood; D018284:Cystadenocarcinoma, Serous / Q000097:blood* / Q000473:pathology / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D005340:Fibrinogen / Q000378:metabolism*; D006801:Humans; D008565:Membrane Proteins / Q000097:blood; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery; D010976:Platelet Count; D011379:Prognosis; D012189:Retrospective Studies; D013922:Thrombocytosis / Q000097:blood* / Q000473:pathology
chemical_list: D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins; D005340:Fibrinogen
references.citation: Int J Gynecol Cancer. 2013 Feb;23(2):276-81
references.pmid: 23266651
references.citation: PLoS One. 2011;6(10):e26125
references.pmid: 22022533
references.citation: Contemp Oncol (Pozn). 2013;17(2):113-9
references.pmid: 23788975
references.citation: J Obstet Gynaecol Res. 2014 Jan;40(1):178-83
references.pmid: 24102732
references.citation: Cancer Res. 2002 Dec 1;62(23):6966-72
references.pmid: 12460914
references.citation: Cancer Cell. 2011 Nov 15;20(5):576-90
references.pmid: 22094253
references.citation: Eur J Intern Med. 2013 Jul;24(5):393-400
references.pmid: 23433737
references.citation: Cancer Res. 2011 Jan 15;71(2):424-34
references.pmid: 21123455
references.citation: Eur J Cell Biol. 2012 Jun-Jul;91(6-7):496-505
references.pmid: 22093287
references.citation: Am J Surg Pathol. 2010 Mar;34(3):433-43
references.pmid: 20154587
references.citation: Arch Gynecol Obstet. 2011 Jul;284(1):183-90
references.pmid: 20680316
references.citation: Gynecol Oncol. 2013 Sep;130(3):499-504
references.pmid: 23747328
references.citation: Clin Cancer Res. 2011 Sep 15;17(18):6083-96
references.pmid: 21795409
references.citation: N Engl J Med. 2012 Feb 16;366(7):610-8
references.pmid: 22335738
references.citation: Int J Gynecol Cancer. 2015 Jan;25(1):24-32
references.pmid: 25347092
references.citation: CA Cancer J Clin. 2015 Mar;65(2):87-108
references.pmid: 25651787
references.citation: J Transl Med. 2005 Jun 21;3:25
references.pmid: 15969748
references.citation: Cell Signal. 2007 Sep;19(9):1866-78
references.pmid: 17543500
references.citation: Nat Rev Cancer. 2011 Feb;11(2):123-34
references.pmid: 21258396
references.citation: Clin Appl Thromb Hemost. 2006 Jan;12(1):3-8
references.pmid: 16444428
references.citation: J Obstet Gynaecol Res. 2012 Apr;38(4):651-7
references.pmid: 22413879
references.citation: Oncologist. 2009 Oct;14(10):979-85
references.pmid: 19776095